Who makes Acthar Gel-Synthetic?

Acthar Gel-Synthetic is developed by Armour Pharm.

What development phase is Acthar Gel-Synthetic in?

Acthar Gel-Synthetic is FDA-approved (marketed).

What is the generic name of Acthar Gel-Synthetic?

seractide is the generic (nonproprietary) name of Acthar Gel-Synthetic.

Last reviewed 2026-04-20 · How we verify

Acthar Gel-Synthetic (seractide)

Armour Pharm · FDA-approved active Quality 15/100

Seractide (Acthar Gel-Synthetic), marketed by Armour Pharm, is a synthetic adrenocorticotropic hormone that regulates cortisol production and holds a significant position in the market with a key composition patent expiring in 2028. Its key strength lies in its mechanism of action, which closely mimics the natural hormone, providing a unique therapeutic approach. The primary risk is the competitive landscape, including bremelanotide and corticotropin, both of which are patent-protected until 2033 and 2043, respectively, potentially limiting Seractide's market share.

At a glance

Generic name	seractide
Sponsor	Armour Pharm
Drug class	seractide
Target	Adrenocorticotropic hormone receptor
Therapeutic area	Nephrology
Phase	FDA-approved
First approval	1978

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acthar Gel-Synthetic CI brief — competitive landscape report
Acthar Gel-Synthetic updates RSS · CI watch RSS
Armour Pharm portfolio CI